11月18日，在外交部例行记者会上，有记者向外交部发言人赵立坚提问：近期，多国企业新冠肺炎疫苗研发取得了新的进展。我们知道，中国有几家企业的疫苗也在多国开展临床试验，你可否介绍更多情况？中方参与疫苗国际合作进展如何？
赵立坚表示：感谢你对中国相关企业疫苗研发进展的关注。疫苗是抵御新冠病毒的有力武器。中国疫苗研发进展可以用两个“五”来概括：
Thank you for your attention on Chinese vaccine R&D. Vaccines are powerful weapons against the coronavirus. China's vaccine development progress can be summed up in two "fives" :
![]()
图源：外交部网站
第一个“五”，新冠肺炎疫情发生以来，中国政府第一时间布局了灭活疫苗、重组蛋白疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗五条技术路线，规范有序开展研发工作。第二个“五”，中国已有5支疫苗正在阿联酋、巴西、巴基斯坦、秘鲁等多国开展III期临床试验，另有多支疫苗正在加紧推进I、II期临床试验。
First, after the pandemic broke out, the Chinese government at the earliest time possible laid out five technical routes including inactivated vaccine, recombinant protein vaccine, adenoviral vector vaccine, attenuated influenza vaccine and nucleic acid vaccine. Vaccine research and development has been carried out in an orderly manner. Second, five Chinese vaccine candidates are under clinical trials in countries including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.
中国疫苗研发单位和广大科研工作者严格依据科学规律和监管要求，夜以继日、全力以赴推进疫苗研发，为此付出艰辛努力。我和大家一样都期待着能够尽早听到他们的好消息。
Following scientific rules and regulations, Chinese researchers and scientists have been working around the clock and making arduous efforts on the vaccines. Like you all, I look forward to hearing good news about them as soon as possible.
视频来源：人民视频
关于疫苗国际合作，中国政府和企业一直积极通过多双边渠道参与疫苗国际合作。除了刚才提到的同有关国家合作开展疫苗研发外，中方也同世界卫生组织、全球疫苗免疫联盟、流行病防范创新联盟等国际组织保持密切沟通与合作，加入了世卫组织“全球合作加速开发、生产、公平获取新冠肺炎防控新工具”倡议和“团结计划”国际多中心临床试验。中方还加入了“新冠疫苗实施计划”，以促进疫苗公平分配，确保为发展中国家提供疫苗，同时带动更多有能力的国家支持“实施计划”。中方期待中国疫苗研发完成后能够尽早被纳入“实施计划”采购清单，为实现疫苗在发展中国家的可及性和可负担性做出自己的贡献。
The Chinese government and companies have been proactively participating in international cooperation on vaccines through bilateral and multilateral channels. Besides cooperation with the countries I talked about earlier, China is also in close communication and cooperation with international organizations such as the WHO, Gavi, the Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations. We are part of the WHO-sponsored Access to COVID-19 Tools (ACT) Accelerator initiative and the Solidarity Trial for COVID-19 treatments. China has also joined COVAX to promote fair distribution of vaccines, ensure the provision of vaccines for developing countries, and encourage more capable countries to support COVAX. We hope Chinese vaccines will be included in COVAX's procurement list as soon as possible after their development, which will contribute to the accessibility and affordability of vaccines in developing countries.
据新华社报道，中国团队17日在英国期刊《柳叶刀•传染病》上发表报告说，他们对新冠病毒灭活疫苗克尔来福开展的Ⅰ/Ⅱ期随机双盲对照临床试验结果显示，这一候选疫苗安全并能在健康志愿者身上诱导产生免疫应答。
A Chinese inactivated COVID-19 vaccine candidate has been proved safe and tolerable and can induce a quick immune response, according to the findings from early and mid-stage clinical trials published in the journal The Lancet Infectious Diseases. The vaccine, CoronaVac, was developed by a Chinese biopharmaceutical producer Sinovac Biotech.
![]()
图源：《柳叶刀•传染病》网站
江苏省疾病预防控制中心等机构的研究人员于4月16日至5月5日对新冠灭活疫苗克尔来福进行了Ⅰ/Ⅱ期随机双盲对照临床试验。团队在中国招募了超过700名18岁至59岁健康志愿者参与试验。
It was tested in randomized, double-blind and placebo-controlled phase-1 and phase-2 clinical trials involving more than 700 healthy adults aged 18 to 59.
报告说，尽管疫苗在志愿者体内诱导出的抗体水平比一些曾感染新冠病毒并已康复的人体内所观察到的抗体水平低，但研究人员认为，该疫苗已可以保护人体不被病毒感染。
The level of antibodies induced by the vaccine was lower than those in people who had recovered from COVID-19, whereas it was capable of protecting the human body from infections caused by the virus, the findings said.
综合来源：新华网，外交部网站
